The purpose of this research study is to evaluate the effect of AZD3199 on the electrical activity of the heart. The effect of AZD3199 will be compared to a licensed antibiotic (moxifloxacin). Moxifloxacin effects on the electrical activity of the heart are well known. Safety and tolerability of AZD3199 and how much AZD3199 enters the blood circulation will also be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
40
Single dose, oral inhalation
Single dose, oral encapsulated tablet
Single dose, oral inhalation
Research Site
London, UK, United Kingdom
To investigate the effect of AZD3199 on the QT interval
QTcF or QTcI (algorithm based decision)
Time frame: Throughout the study
To investigate the effect of AZD3199 on additional electrocardiogram variables
* QTcF or QTcI dependent on variable confirmed as primary * Holter-Bin QT
Time frame: Throughout the study
To assess the pharmacokinetics of single doses of AZD3199.
* AUC(0-24) * Cmax * tmax
Time frame: Throughout the study
To evaluate the safety and tolerability of single doses of AZD3199.
* Adverse events - type of events and number of subjects experiencing adverse events. * Laboratory safety assessments, pulse, blood pressure and electrocardiogram interpretation - Summarised using descriptive stats. Judged regarding high/low values or changes from pre-dose.
Time frame: Throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.